Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes.
T cell mediated immunotherapies are proposed for many cancers including malignant astrocytoma. As such therapies become more potent, but not necessarily more tumor-specific, the risk of collateral autoimmune damage to normal tissue increases. Tumors of the brain present significant challenges in this respect, as autoimmune destruction of brain tissue could have severe consequences. To investigate local immune reactivity toward a tumor-associated antigen in the brain, transgenic mice were generated that express a defined antigen (CW3 170-179) in astroglial cells. The resulting six transgenic mouse lines expressed the transgenic self-antigen in cells of the gastrointestinal tract and CNS compartments, or in the CNS alone. By challenging transgenic mice with tumor cells that express CW3, self/tumor-specific immune responses were visualized within a normal polyclonal T cell repertoire. A large expansion of the endogenous CW3 170-179-specific CD8 T cell population was observed in nontransgenic mice after both subcutaneous and intracerebral implantation of tumor cells. In contrast, CW3 170-179-specific immune responses were not observed in transgenic mice that exhibited extracerebral transgene expression. Importantly, in certain groups of mice in which transgene expression was restricted to the CNS, antigen-specific immune responses occurred when tumor was implanted subcutaneously, but not intracerebrally. This local immune tolerance in the brain was induced via peripheral (extrathymic) rather than central (thymic) tolerance mechanisms. Thus, this study highlights the role of regional immune regulation in the prevention of autoimmunity in the brain, and the potential impact of these mechanisms for brain tumor immunotherapy.
Centre of Oncology, Geneva University Hospitals and University of Geneva, rue Micheli-du-Crest 24, Geneva, Switzerland.
Thomas
T
Calzascia
Jacelyn M S
JM
Loh
Wilma
W
Di Berardino-Besson
Frédérick
F
Masson
Philippe
P
Guillaume
Karim
K
Burkhardt
Pedro L
PL
Herrera
Pierre-Yves
PY
Dietrich
Paul R
PR
Walker
D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001253:Astrocytes / Q000276:immunology* / Q000473:pathology; D001254:Astrocytoma / Q000276:immunology* / Q000503:physiopathology; D001324:Autoantigens / Q000235:genetics / Q000276:immunology; D020274:Autoimmune Diseases of the Nervous System / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D015551:Autoimmunity / Q000235:genetics / Q000276:immunology; D001921:Brain / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D001932:Brain Neoplasms / Q000276:immunology* / Q000503:physiopathology; D016380:Brain Tissue Transplantation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D007108:Immune Tolerance / Q000276:immunology*; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D051379:Mice; D008822:Mice, Transgenic; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D001324:Autoantigens